Syros Pharmaceuticals, Inc.

DB:0S90 Stock Report

Market Cap: €6.7m

Syros Pharmaceuticals Valuation

Is 0S90 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0S90 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0S90's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0S90's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0S90?

Key metric: As 0S90 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0S90. This is calculated by dividing 0S90's market cap by their current revenue.
What is 0S90's PS Ratio?
PS Ratio20.3x
SalesUS$386.00k
Market CapUS$6.98m

Price to Sales Ratio vs Peers

How does 0S90's PS Ratio compare to its peers?

The above table shows the PS ratio for 0S90 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
CNW co.don
0.7xn/a€6.5m
MDG1 Medigene
3x16.1%€22.6m
ECX Epigenomics
7.7xn/a€1.2m
BPXA Bellicum Pharmaceuticals
0.5xn/a€772.4k
0S90 Syros Pharmaceuticals
20.3x11.3%€7.0m

Price-To-Sales vs Peers: 0S90 is expensive based on its Price-To-Sales Ratio (20.3x) compared to the peer average (4.2x).

Price to Sales Ratio vs Industry

How does 0S90's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
0S90 20.3xIndustry Avg. 7.9xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0S90 is expensive based on its Price-To-Sales Ratio (20.3x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0S90's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0S90 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0S90's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Perrigo

US$3.7b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$25.74

7D

1.9%

1Y

-7.4%

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Merck

US$252.6b

Operates as a healthcare company worldwide.

6MK

US$97.10

7D

6.7%

1Y

3.9%